in the absence of a submission from the holder of the marketing authorisation:
brentuximab vedotin (Adcetris®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice214KB (PDF)
- Medicine name:
- brentuximab vedotin (Adcetris)
- SMC ID:
- treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 09 July 2018